Polyoma virus middle T antigen inhibitors represent a specialized group of chemical entities that exhibit a unique affinity for targeting the Polyoma virus middle T antigen. This viral antigen is known to exert a notable influence on various intracellular pathways, including those related to cellular growth, proliferation, and transformation. The chemical class of these inhibitors encompasses a range of structurally diverse compounds, each meticulously designed to interact with specific binding pockets or active sites within the middle T antigen. The rational design of these inhibitors involves an in-depth understanding of the three-dimensional structure of the Polyoma virus middle T antigen and the identification of key residues and domains that are crucial for its functional activity. By strategically exploiting these structural insights, researchers have endeavored to develop compounds that can effectively disrupt the interactions between the middle T antigen and its host cellular partners. This disruption can lead to a cascade of downstream effects, influencing vital cellular processes.
Innovative synthetic strategies have been employed to create diverse analogs within the Polyoma virus middle T antigen inhibitors class. These analogs are systematically modified to enhance their binding affinity, selectivity, and pharmacokinetic properties. Such modifications might include altering chemical moieties, optimizing stereochemistry, and fine-tuning the overall molecular architecture of the inhibitors. The investigation into Polyoma virus middle T antigen inhibitors not only contributes to expanding the repertoire of available chemical tools for molecular research but also offers a window into the intricate interactions that govern viral-host interactions. The class of inhibitors facilitates studies aimed at unraveling the mechanistic underpinnings of the Polyoma virus middle T antigen's role in cellular transformation and proliferation. Through this exploration, researchers aim to gain deeper insights into the fundamental cellular processes influenced by the middle T antigen and, in turn, enhance our understanding of cellular biology at a molecular level.
SEE ALSO...
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $184.00 $321.00 | 1 | |
Targets pathways downstream of PyMT. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Initially for multiple myeloma, it affects the breakdown of proteins. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Halts signaling pathways connected to PyMT. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
Stops the MAPK pathway involved in PyMT-driven transformation. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
First developed for leukemia, it targets Src kinases. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Impairs tyrosine kinases, influencing angiogenesis and proliferation. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Affects multiple kinases, impacting angiogenesis and proliferation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Blocks CDK4/6, affecting the progression of the cell cycle. |